(3R,4S)-Tofacitinib - CAS 1092578-46-5
Catalog number: 1092578-46-5
Category: Inhibitor
Not Intended for Therapeutic Use. For research use only.
Molecular Formula:
C16H20N6O
Molecular Weight:
312.37
COA:
Inquire
Targets:
JAK
Description:
Tofacitinib is a novel inhibitor of JAK3 with IC50 of 1 nM, 20- to 100-fold less potent against JAK2 and JAK1.
Publictions citing BOC Sciences Products
  • >> More
Purity:
>98%
Synonyms:
CP-690550
MSDS:
Inquire
1.Examining the chirality, conformation and selective kinase inhibition of 3-((3R,4R)-4-methyl-3-(methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)piperidin-1-yl)-3-oxopropanenitrile (CP-690,550).
Jiang JK1, Ghoreschi K, Deflorian F, Chen Z, Perreira M, Pesu M, Smith J, Nguyen DT, Liu EH, Leister W, Costanzi S, O'Shea JJ, Thomas CJ. J Med Chem. 2008 Dec 25;51(24):8012-8. doi: 10.1021/jm801142b.
Here, we examine the significance that stereochemistry plays within the clinically relevant Janus kinase 3 (Jak3) inhibitor 1 (CP-690,550). A synthesis of all four enantiopure stereoisomers of the drug was carried out and an examination of each compound revealed that only the enantiopure 3R,4R isomer was capable of blocking Stat5 phosphorylation (Jak3 dependent). Each compound was profiled across a panel of over 350 kinases, which revealed a high level of selectivity for the Jak family kinases for these related compounds. Each stereoisomer retained a degree of binding to Jak3 and Jak2 and the 3R,4S and 3S,4R stereoisomers were further revealed to have binding affinity for selected members of the STE7 and STE20 subfamily of kinases. Finally, an appraisal of the minimum energy conformation of each stereoisomer and molecular docking at Jak3 was performed in an effort to better understand each compounds selectivity and potency profiles.
Molecular Weight Calculator Molarity Calculator Solution Dilution Calculator

Related JAK Products


CAS 937272-79-2 Pacritinib

Pacritinib
(CAS: 937272-79-2)

Pacritinib, also known as SB1518, is an orally bioavailable inhibitor of Janus kinase 2 (JAK2) and the JAK2 mutant JAK2V617F with potential antineoplastic acti...

CAS 1208319-26-9 Oclacitinib

Oclacitinib
(CAS: 1208319-26-9)

Oclacitinib, also known as PF03394197, is a novel Janus kinase inhibitor with activity against cytokines involved in allergy. Oclacitinib inhibited JAK family m...

CAS 1092939-17-7 Ruxolitinib phosphate

Ruxolitinib phosphate
(CAS: 1092939-17-7)

Ruxolitinib phosphate is the first potent, selective, JAK1/2 inhibitor to enter the clinic with IC50 of 3.3 nM/2.8 nM, >130-fold selectivity for JAK1/2 versus J...

CAS 457081-03-7 Pyridone 6

Pyridone 6
(CAS: 457081-03-7)

Pyridone 6 is a potent and selective inhibitor of JAK1, JAK2, JAK3, and Tyk2, displaying significantly weaker affinities for other protein tyrosine kinases. It ...

CAS 540737-29-9 Tofacitinib Citrate

Tofacitinib Citrate
(CAS: 540737-29-9)

Tofacitinib (trade name Xeljanz, formerly tasocitinib, CP-690550) is a drug discovered and developed by Pfizer. It is currently approved for the treatment of rh...

CAS 1837-91-8 1,2,3,4,5,6-Hexabromocyclohexane

1,2,3,4,5,6-Hexabromocyclohexane
(CAS: 1837-91-8)

1,2,3,4,5,6-Hexabromocyclohexane is a potent inhibitor of JAK2 tyrosine kinase autophosphorylation. It inhibits JAK2 activation, and reduces growth hormone-medi...

CAS 1056634-68-4 Cyt387

Cyt387
(CAS: 1056634-68-4)

Cyt387, also called Momelotinib, under the IUPAC name N-(cyanomethyl)-4-(2-((4-(4-morpholinyl)phenyl)amino)-4-pyrimidinyl)benzamide, is an ATP competitive inhib...

CAS 1187595-84-1 Baricitinib phosphate

Baricitinib phosphate
(CAS: 1187595-84-1)

IC50 Value: JAK1 (5.9 nM) and JAK2 (5.7 nM). Baricitinib, also known as INCB028050 or LY3009104, is a selective orally bioavailable JAK1/JAK2 inhibitor with nan...

CAS 1204918-72-8 SB1317

SB1317
(CAS: 1204918-72-8)

SB1317 is a novel small molecule potent CDK/JAK2/FLT3 inhibitor. It dose-dependently inhibits signaling pathways downstream of CDKs, JAK2 and FLT3 in cancer cel...

CAS 944842-54-0 Decernotinib

Decernotinib
(CAS: 944842-54-0)

Decernotinib, also known as VX-509 or VRT-831509 or adelatinib, is an oral, selective Janus kinase 3 (JAK3) inhibitor being developed by Vertex. VX-509 may repr...

Upadacitinib
(CAS: 1310726-60-3)

Upadacitinib is a selective JAK inhibitor under the development of AbbVie.ABT-494 is nearly 74 fold selective for Jak1 over Jak2 in cellular assays dependent on...

CAS 80418-25-3 20(S)-Notoginsenoside R2

20(S)-Notoginsenoside R2
(CAS: 80418-25-3)

20(S)-Notoginsenoside R2 is a natural product extracted from the roots of Panax notoginseng (Burk.) F.H.Chen. It has neuroprotection against 6-OHDA-induced neur...

CAS 477600-75-2 Tofacitinib

Tofacitinib
(CAS: 477600-75-2)

Tofacitinib (CP-690550,Tasocitinib) is a novel inhibitor of JAK3 with IC50 of 1 nM, 20- to 100-fold less potent against JAK2 and JAK1.It is currently approved f...

NS-018
(CAS: 1239358-86-1)

NS-018, a selective JAK2 as well as Src family tyrosine kinases inhibitor that could probably induce the apoptosis of tumor cells. It is still under Phase I/II ...

CAS 944118-01-8 Peficitinib

Peficitinib
(CAS: 944118-01-8)

Peficitinib, also known as ASP015K and JNJ-54781532, is a novel potent JAK inhibitor, which demonstrated potent efficacy in adjuvant-induced arthritis model in ...

CAS 916742-11-5 R-932348

R-932348
(CAS: 916742-11-5)

A dual JAK/SYK inhibitor that can be used to treat diseases and disorders of the eye.

CAS 1895895-38-1 CHZ868

CHZ868
(CAS: 1895895-38-1)

CHZ868 is a potent and selective type II JAK2 inhibitor (IC50= 0.17 μM in EPOR JAK2 WT Ba/F3 cell). CHZ868 potently inhibited proliferation of cells expressing ...

CAS 82058-16-0 NSC 33994

NSC 33994
(CAS: 82058-16-0)

NSC-33994 is a selective inhibitor of JAK2 with IC50 of 60 nM.

CAS 1260181-14-3 TCS 21311

TCS 21311
(CAS: 1260181-14-3)

TCS 21311 is a potent JAK3 inhibitor (IC50 = 8 nM) with selectivity for JAK3 over JAK1, JAK2 and TYK2 (IC50 = 1017, 2550 and 8055 nM, respectively). It also inh...

CAS 1229236-86-5 LY2784544

LY2784544
(CAS: 1229236-86-5)

Gandotinib is a potent and selective JAK inhibitor, which effectively inhibited JAK2V617F-driven signaling and cell proliferation in Ba/F3 cells (IC50=20 and 55...

Chemical Structure

CAS 1092578-46-5 (3R,4S)-Tofacitinib

Quick Inquiry

Verification code

Featured Items